

Figure S1. Impact of heparin derivatives on platelet aggregation and secretion. (**A,B**) Representative traces showing platelet-tumor cell aggregation in response to MDA-MB-231 cells. Platelets were preincubated with (**A**) 100 µg/mL RO-heparin or (**B**) 100 µg/mL 2-O-desulfated heparin. (**C**) Quantification of ATP release from MDA-MB-231 cell stimulated platelets preincubated with 100 µg/mL RO-heparin, or 100 µg/mL 2-O-desulfated heparin. (**D,E**) Representative traces showing platelet-tumor cell aggregation in response to MDA-MB-231 cells, platelets were preincubated with (**D**) 100 µg/mL hexasaccharide or (**E**) 100 µg/mL decasaccharide (n = 5). (**F**) Quantification of ATP release from MDA-MB-231 cell stimulated platelets preincubated with 100 µg/mL hexasaccharide, or 100 µg/mL decasaccharide. (**G**) Representative traces showing platelet-tumor cell aggregation in response to MDA-MB-231 cells. Tumor cells were preincubated with 1 µg/1000 cells recombinant human P-selectin (n = 5). (**H**) Representative traces showing platelet-tumor cell aggregation in response to MDA-MB-231 cells. Platelets were preincubated with 100 µg/mL P-selectin inhibitor (n = 5). (**I**) Quantification of ATP release from MDA-MB-231 cell (preincubated with 1 µg recombinant human P-selectin/1000 cells in some experiments) stimulated platelets preincubated with 100 µg/mL P-selectin inhibitor.